A 57-year-old woman presented with systemic inflammatory response syndrome manifesting as highgrade fever over the past 2 months, unexplained fatigue, malaise, weight loss, night sweats, diffuse nonspecific arthralgias and myalgias. The patient had a history of hypertension for 2 years. The physical examination, with a focus on pulse assessment, bruit auscultation, and inter-arm systolic blood pressure difference, was not suggestive of arterial disease. Laboratory results showed leukocytosis (12,100/μL), elevated erythrocyte sedimentation rate (72 mm/h), and C-reactive protein level (131 mg/L). No clear focus of infection was found. A transthoracic echocardiogram was negative for infective endocarditis. Contrast-enhanced computed tomography of the chest, abdomen, and pelvis did not reveal clinically important abnormalities. With a suspicion of an occult malignancy, the patient underwent whole-body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/ CT) that showed increased 18F-FDG uptake in the thoracic and abdominal aorta expanding to the subclavian, common carotid, and femoral arteries (Figure 1). In the setting of systemic inflammatory response syndrome, we judged these images to be compatible with large vessel vasculitis (LVV). The patient initiated treatment with methylprednisolone and methotrexate, resulting in significant improvement of symptoms and reduction of inflammatory markers.LVV is characterized by predominant but not exclusive involvement of the aorta and its major branches, with Takayasu arteritis (TAK) and giant-cell arteritis (GCA) being the two major variants (1). The margin between GCA and TAK is blurred, and the histopathological findings are indistinguishable (2). This case illustrates the central role of 18F-FDG PET/CT findings in early diagnosis of LVV in a patient with unexplained systemic disease. PET/CT imaging reveals increased metabolic activity when morphological changes (like wall thickening, arterial stenosis, or dilatation) and overt vascular symptoms (such as pulselessness, bruits, blood pressure difference) are absent (3). Therefore, when diagnosed in an early stage, most patients would not meet the existing 1990 American College of Rheumatology classification criteria for either GCA or TAK, as these criteria are appropriate for advanced cases. Moreover, these criteria do not consider the possibility of using novel imaging modalities (4). Cases of early diagnosis of both GCA and pre-pulseless TAK with improved imaging techniques are increasingly reported (5). Therefore, we suggest that the time has come to update the classification criteria for LVV, which are currently not working at an early stage of the disease (3).
Background. Tracer production for nuclear medicine. Objective. The aim of the paper is to consider the possibility of 99m Tc tracer production using low-energy medical cyclotrons installed in Ukraine applying enriched 100 Мо targets. Tc tracer yield equals 3.7 and 35.5 GBq after 2h of bombardment for Eclipse RD and PETtrace cyclotrons, respectively. Conclusions. The obtained results showed satisfied 99m Tс tracer yields and feasibility of further development of this method, which will significantly improve the efficiency of cyclotron installations.
was performed by Kaplan-Meier curves and Log-Rank test.Statistical significance was considered for values of p <0.05.Results: PET CT images of 78 patients were centrally reviewed. All patients are currently alive (OS=100%). After a median follow-up of 60 months (range 17-139) 17 patients (21%) had disease recurrence, with RFS of 60% at 104 months (median not reached). The median time to relapse was 8 months (range 3-39). Splenic involvement, anemia (Hb<12 gr/dl) and bulky disease at diagnosis increased risk of relapse. Patients with EoT DS1 (56 cases) showed 83% RFS at 100 months (median not reached). Median RFS worsened for higher DS: 77 months for DS2 (12 cases), 2 months for DS3 (2 cases), 26 months for DS 4 (3 cases), and 14 months for DS5 (p <0.001) [Shown in figure]. There was a longer time frame to relapse in DS1/2 compared to DS≥3 (median time of 34 and 4 months respectively). Comparing I-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.